Mainstay Medical International announced it has received authorization from the Belgian Federal Agency for Medicines and Health Products to expand the clinical trial of ReActiv8, its implantable neurostimulation device, to include additional trial sites in Belgium.
The trial, which started in Australia, aims at investigating ReActiv8 as a treatment for adults with debilitating chronic low back pain.
Enrollment of subjects is starting in the additional sites in Belgium.
More Articles on Devices:
5 Key Results: LDR's Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE's Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018